All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Australian Ethical
Deal Size: $22.4 million Upfront Cash: Undisclosed
Deal Type: Financing November 19, 2020
Details:
The Company will use the proceeds to finance its LAG-3 related clinical program in immuno-oncology and autoimmune disease. The funds will also be used for the cell-line development of IMP761, R&D, manufacturing, the offering costs and working capital purposes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Paxalisib
Therapeutic Area: Oncology Product Name: GDC-0084
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2020
Details:
The new interim analysis of paxalisib phase II study in glioblastoma is highly consistent with prior data. Median progression-free survival (PFS) of 8.4 months reported on this analysis (versus 5.3 months for temozolomide, the existing standard of care).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: Efti
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
The study is evaluating combination of efti with MSD’s KEYTRUDA® (pembrolizumab) in up to 109 patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2020
Details:
More mature interim data from phase II TACTI-002 study of eftilagimod alpha has been accepted as a late breaker poster presentation and poster walk for highly scored abstracts at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary 2020 Annual Meeting.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Paxalisib
Therapeutic Area: Oncology Product Name: GDC-0084
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $25.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 23, 2020
Details:
Cash outflows are likely to increase as the Company proceeds with the GBM Agile trial, he pivotal study for registration of paxalisib in glioblastoma.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2020
Details:
TACTI-002 is being conducted in collaboration with Merck & Co and is evaluating the combination of Immutep’s lead candidate, eftilagimod alpha with MSD’s KEYTRUDA in up to 109 patients with second line Head and Neck Squamous Cell Carcinoma or NSCLC in first and second line.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
Details:
This U.S patent protects Immutep’s intellectual property relating to combined therapeutic preparations comprising its lead active immunotherapy candidate eftilagimod alpha and a chemotherapy agent.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IMP701,Spartalizumab
Therapeutic Area: Oncology Product Name: LAG525
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2020
Details:
This new United States patent is directed to embodiments of LAG525, a humanised form of Immutep’s IMP701 antibody which is out-licensed to Novartis AG.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eftilagimod Alpha,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co. Inc.
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2020
Details:
TACTI-002 is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA and is evaluating the combination of Immutep’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”) with MSD’s KEYTRUDA® (pembrolizumab).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Paxalisib
Therapeutic Area: Oncology Product Name: GDC-0084
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
Previous paxalisib data presented at ASCO was based on Stage 1 (n=9) of the ongoing phase II study in glioblastoma. This interim analysis at AACR includes all patients in the study (n=30), and therefore provides a more robust and substantial data set.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
